Press Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN Presents Data on PN 100 Combination Product--Designed to Help Prevent NSAID-Induced Gastric Complications; Proof-of-Concept Study Presentation at American College of Gastroenterology (ACG) Annual Meeting

HONOLULU & CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 2, 2005--POZEN Inc. (NASDAQ: POZN) is presenting key data from its PN 100 proof-of-concept study today during the American College of Gastroenterology Annual Meeting in Honolulu, Hawaii. POZEN's PN product platform, which includes PN 100, consists of combinations of a gastric acid inhibitor and a non-steroidal anti-inflammatory drug (NSAID). These drug candidates may lower the risk of gastrointestinal complications in patients who use NSAID therapy for arthritis and other chronic conditions. POZEN's PN 100 drug candidate is a fixed combination of the proton pump inhibitor (PPI) lansoprazole and the NSAID naproxen, both of which have been used as individual drugs for a number of years.

Dr. James Alexander, POZEN's senior vice president of product development and chief medical officer, is presenting results of a 14-day proof-of-concept study in which volunteers received either PN 100, naproxen alone, or naproxen with a currently marketed once-daily dose of lansoprazole. Dr. Alexander stated, "The key finding of this trial is that PN 100 appears to work very well as evidenced by the fact that PN 100 significantly reduced gastric damage due to naproxen during the study period. This positive effect was evident even in this small proof-of-concept trial."

POZEN's PN drug candidates are being developed for the management of pain and inflammation associated with conditions such as osteoarthritis, one of the most frequent causes of physical disability among adults, affecting an estimated 20 to 30 million people in the United States. Estimates show that by 2030, 20 percent of Americans--about 70 million people--will have passed their 65th birthday and will be at risk of osteoarthritis.

The PN 100 proof-of-concept study presentation slides can be accessed in the Investor Overview section of POZEN's website at


POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN is also exploring the development of product candidates in other acute and chronic pain and pain-related therapeutic areas. POZEN has a development and commercialization alliance with GlaxoSmithKline. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website:

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended June 30, 2005 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Bill Hodges, Chief Financial Officer, 919-913-1030
Fran Barsky, Director, Investor Relations, 919-913-1044


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.